Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

Journal of Thoracic Oncology

Volumn 10, Issue 9, 2015, Pages 1319-1327

  Vansteenkiste, Johan F ^a   Canon, Jean Luc ^b   Braud, Filippo De ^c   Grossi, Francesco ^d   De Pas, Tommaso ^e   Gray, Jhanelle E ^f   Su, Wu Chou ^g   Felip, Enriqueta ^h   Yoshioka, Hiroshige ⁱ   Gridelli, Cesare ^j   Dy, Grace K ^k   Thongprasert, Sumitra ^l   Reck, Martin ^m   Aimone, Paola ⁿ   Vidam, Gena Atalla ⁿ   Roussou, Pantelia ⁿ   Wang, Ying A ^o   Di Tomaso, Emmanuelle ^o   Soria, Jean Charles ^p  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Grand Hopital de Charleroi   (Belgium)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^h VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

ⁱ KURASHIKI CENTRAL HOSPITAL   (Japan)

^j S G MOSCATI HOSPITAL   (Italy)

^k ROSWELL PARK CANCER INSTITUTE   (United States)

^l CHIANG MAI UNIVERSITY   (Thailand)

^m Member of the German Center for Lung Research   (Germany)

ⁿ NOVARTIS PHARMA AG   (Switzerland)

^o NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^p INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Buparlisib BKM120; Nonsquamous NSCLC; PI3K pathway activation; Squamous NSCLC

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUPARLISIB; CARBOPLATIN; CISPLATIN; DNA; GEMCITABINE; K RAS PROTEIN; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TENSIN; AMINOPYRIDINE DERIVATIVE; MORPHOLINE DERIVATIVE; NVP-BKM120;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARDIOGENIC SHOCK; CAUSE OF DEATH; CONFUSION; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVATION; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; LIVER TOXICITY; LUNG LOBECTOMY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTIMODALITY CANCER THERAPY; NAUSEA; NON SMALL CELL LUNG CANCER; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHYSICAL DISABILITY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; RESPIRATORY FAILURE; RISK ASSESSMENT; SEPSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; VISUAL HALLUCINATION; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY;

AGED; AMINOPYRIDINES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORPHOLINES; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84940105287     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000607     Document Type: Article

References (32)

1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E, European cancer mortality predictions for the year 2014. Ann Oncol 2014 25 1650 1656
2. Howlader N, Noone A, Krapcho M, SEER cancer statistics review, 1975-2008. Bethesda MD Natl Cancer Inst 2011 19
3. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer Version 4.2014. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed February 7, 2015.
4. Leighl NB, Treatment paradigms for patients with metastatic non-small-cell lung cancer: First-, second-, and third-line. Curr Oncol 2012 19 Suppl 1 S52 S58
5. Hanna N, Shepherd FA, Fossella FV, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 22 1589 1597
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 353 123 132
7. Scagliotti G, Hanna N, Fossella F, The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies. Oncologist 2009 14 253 263
8. Garassino MC, Martelli O, Broggini M, TAILOR trialists Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised controlled trial. Lancet Oncol 2013 14 981 988
9. Engelman JA, Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009 9 550 562
10. The Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012 489 519 525
11. Yamamoto H, Shigematsu H, Nomura M, PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008 68 6913 6921
12. Perez-Moreno P, Brambilla E, Thomas R, Soria JC, Squamous cell carcinoma of the lung: Molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012 18 2443 2451
13. Courtney KD, Corcoran RB, Engelman JA, The PI3K pathway as drug target in human cancer. J Clin Oncol 2010 28 1075 1083
14. Bianco R, Shin I, Ritter CA, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003 22 2812 2822
15. Jin G, Kim MJ, Jeon HS, PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010 69 279 283
16. Marsit CJ, Zheng S, Aldape K, PTEN expression in non-small-cell lung cancer: Evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005 36 768 776
17. Sos ML, Fischer S, Ullrich R, Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 2009 106 18351 18356
18. Zito CR, Jilaveanu LB, Anagnostou V, Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS One 2012 7 e31331
19. Engelman JA, Chen L, Tan X, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008 14 1351 1356
20. Maira SM, Pecchi S, Huang A, Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012 11 317 328
21. Koul D, Shen R, LaFortune TA, NVP-BKM120: A selective pan-PI3 kinase inhibitor induces G2/M arrest in glioma cell lines via FOXO3a and GADD45a loop. Cancer Res 2010 70 Suppl 8 abstr 350
22. Schnell CR, Arnal S, Becquet M, NVP-BKM120, a pan class I PI3K inhibitor impairs microvascular permeability and tumor growth as detected by DCE-MRI and IFP measurements via radio-telemetry: Comparison with NVP-BEZ235. Cancer Res 2010 70 Suppl 8 abstr 4472
23. Maira S-M, Menezes D, Pecchi S, NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models. Cancer Res 2010 70 Suppl 8 abstr 4497
24. Voliva CF, Pecchi S, Burger M, Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials. Cancer Res 2010 70 Suppl 8 abstr 4498
25. Hurst CD, Zuiverloon TC, Hafner C, Zwarthoff EC, Knowles MA, A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes 2009 2 66
26. Rodon J, Braña I, Siu LL, Phase I dose-escalation and-expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014 32 670 681
27. Saal LH, Holm K, Maurer M, PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005 65 2554 2559
28. Dy GK, Vansteenkiste J, Thomas M, Epidemiology of PI3K pathway alterations in patients with metastatic non-small cell lung cancer (NSCLC): Findings from the international BASALT-1 study. J Thorac Oncol 2013 8 Suppl 2 abstr O04.05
29. The Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014 511 543 550
30. Goss G, Felip E, Cobo M, A randomized, open-label, phase III trial of afatinib (A) Vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Lux-Lung 8 (LL8). Ann Oncol 2014 25 Suppl 4 abstr 1222O
31. McCubrey JA, Steelman LS, Chappell WH, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007 1773 1263 1284
32. Fruman DA, Rommel C, PI3K and cancer: Lessons, challenges and opportunities. Nat Rev Drug Discov 2014 13 140 156